NCT05182905 - AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions

GlioblastomaGliomaGlioblastoma MultiformeGlioma, Malignant

Interventions

DRUG

AZD1390

"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"

Trial Locations (1)

85013

RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix